Amgen wins broader use of Kyprolis in multiple myeloma
This article was originally published in Scrip
Executive Summary
The FDA on 24 July gave Amgen and its subsidiary Onyx Pharmaceuticals the go-ahead to market Kyprolis (carfilzomib) in combination with Celgene's Revlimid (lenalidomide) and dexamethasone (KRd) to treat patients with relapsed multiple myeloma who have received one to three prior lines of therapy.